EMA accepts Merck's ridaforolimus submission, triggering $25M Ariad milestone
This article was originally published in Scrip
Executive Summary
Ariad has announced that the marketing authorisation application (MAA) that its partner Merck submitted to the European Medicines Agency (EMA) in late July for the investigational mTOR inhibitor ridaforolimus as a treatment for patients with metastatic sarcomas has been accepted for review.